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ABSTRACT
Objectives To assess whether the mortality benefit from
screeningmenaged65-74forabdominalaorticaneurysm
decreases over time, and to estimate the long term cost
effectiveness of screening.
Design Randomised trial with 10 years of follow-up.
SettingFourcentresintheUK.Screeningandsurveillance
wasdeliveredmainlyinprimarycaresettings,withfollow-
up and surgery offered in hospitals.
Participants Population based sample of 67770 men
aged 65-74.
Interventions Participants were individually allocated to
invitation to ultrasound screening (invited group) or to a
control group not offered screening. Patients with an
abdominal aortic aneurysm detected at screening
underwent surveillance and were offered surgery if they
met predefined criteria.
Main outcome measures Mortality and costs related to
abdominalaorticaneurysm,andcostperlifeyeargained.
Results Over 10 years 155 deaths related to abdominal
aortic aneurysm (absolute risk 0.46%) occurred in the
invited group and 296 (0.87%) in the control group
(relative risk reduction 48%, 95% confidence interval
37%to57%).Thedegreeofbenefitseeninearlieryearsof
follow-up was maintained in later years. Based on the
10 year trial data, the incremental cost per man invited to
screening was £100 (95% confidence interval £82 to
£118), leading to an incremental cost effectiveness ratio
of £7600 (£5100 to £13000) per life year gained.
However, the incidence of ruptured abdominal aortic
aneurysms in those originally screened as normal
increased noticeably after eight years.
Conclusions The mortality benefit of screening men aged
65-74 for abdominal aortic aneurysm is maintained up to
10yearsandcosteffectivenessbecomesmorefavourable
over time. To maximise the benefit from a screening
programme, emphasis should be placed on achieving a
high initial rate of attendance and good adherence to
clinical follow-up, preventing delays in undertaking
surgery, and maintaining a low operative mortality after
elective surgery. On the basis of current evidence,
rescreening of those originally screened as normal is not
justified.
Trial registration Current Controlled Trials
ISRCTN37381646.
INTRODUCTION
National screening programmes for abdominal aortic
aneurysm in men have recently been introduced in
England and Scotland
12 and in the United States as
part of Medicare.
3 The United Kingdom Multicentre
Aneurysm Screening Study (MASS)
45 has provided
most of the worldwide randomised evidence for the
mortality benefit after ultrasound screening for
abdominal aortic aneurysm.
67The UK screening pro-
grammeformenaged65isbasedcloselyontheproto-
col and procedures in MASS. Some uncertainties
relating to screening remain, however, including its
long term benefit in terms of mortality and cost effec-
tiveness, whether rescreening those with a previously
normalscaniswarranted,andtheextenttowhichinci-
dental detection of abdominal aortic aneurysm erodes
the benefit of a systematic screening policy over time.
It might be expected that the mortality benefit seen in
the early years after one-off screening would decrease
over time. MASS, started in 1997, runs more than
10 years ahead of the UK national screening pro-
gramme and is uniquely positioned to tackle these
uncertainties and to inform the development of the
national programme.
Results from MASS were last published after seven
years of follow-up.
5 The only existing evidence from
randomised trials after seven years comes from the
much smaller Chichester trial,
8 in which a possibly
substantial increase in ruptured abdominal aortic
aneurysms among participants screened as normal
was noted during later follow-up.
9 Such an increase
would reduce the long term benefit from a single
initial scan. Moreover, long term cost effectiveness
has been estimated only through health economic
modelling,
1011 and such models extrapolated from
short term data may be misleading.
1213 To provide
more reliable evidence, we present new information
from the 10 years of follow-up now available in
MASS.
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The design of MASS is described in detail elsewhere.
4
Briefly,apopulationbasedsampleof67770menaged
65-74wasrecruitedduring1997-9fromfourcentresin
the UK and randomised to receive an invitation to
screening for abdominal aortic aneurysm (invited
group) or not (control group). Among the 33883 men
invited to screening, principally in a primary care set-
ting, 27204 (80%) attended and 1334 aneurysms (dia-
meter ≥3.0 cm) were detected. Within this group of
detectedaneurysms,surveillanceinvolvedrescanning:
annually for those with diameters of 3.0-4.4 cm and
every three months for those of 4.5-5.4 cm. Patients
werereferredtoahospitaloutpatientclinicforpossible
elective surgery when the aneurysm reached 5.5 cm,
the aneurysm had expanded by 1.0 cm or more in
one year, or symptoms attributable to the aneurysm
were reported.
We collected additional data from local hospital
records on follow-up ultrasound scanning done within
medical imaging departments and surgery for abdom-
inal aortic aneurysm. The UK Office for National Sta-
tistics notified us of deaths up to 31 March 2008, after
matching on the unique National Health Service
(NHS) number for each participant. Follow-up ranged
from 8.9 to 11.2 years (mean 10.1 years). The primary
outcome of interest—deaths related to abdominal aor-
ticaneurysm—isdefinedasalldeathswithin30daysof
anysurgery(electiveoremergency)forabdominalaor-
tic aneurysm plus all deaths with codes 441.3-441.6
(international classification of diseases, ninth revision;
see table 1).
We used unadjusted Cox regression to compare
deaths related to abdominal aortic aneurysm (censor-
ing other causes of death) and all cause mortality
betweenthetworandomisedgroups.Lifeyearsgained
was derived as the area between the Kaplan-Meier
curves of deaths related to abdominal aortic aneurysm
for the control and invited groups, adjusting for the
effect of deaths from other causes.
14 We also obtained
an unbiased randomisation based estimate of the ben-
efit of attending initial screening.
15 This estimate was
calculated by subtracting from the controls a group
that is equivalent to the non-attending group among
thoseinvited,thusleavingacontrolgroupcomparable
to those attending in the invited group.
We estimated the cost effectiveness of screening
from a UK health service perspective, for follow-up
truncated at 10 years. The relevant unit costs are
taken from a recent UK Department of Health
report
16; these are based on a detailed costing exercise
at 2000-1 prices
17 uplifted to reflect 2008-9 prices.
Events costed include each invitation to screening
(£1.74; €2.02; $2.88), reinvitation to screening
(£1.70),initial scan(£25.31),recallscan(£61.07),refer-
ral for consideration for elective surgery (£411.07),
elective surgery (£9165), and emergency surgery
(£14825). We applied discounting at the currently
recommended rate of 3.5% per year for both costs
andeffects.Incrementalcostsandthecosteffectiveness
ratio take into account censoring at the end of follow-
up by dividing the follow-up into intervals of six
months.
1819 We used Fieller’s method to calculate the
confidence interval for the incremental cost effective-
ness ratio.
20
RESULTS
The flow of participants in the trial is as reported
previously,
5 except for two features. Firstly, of the
1334 men with abdominal aortic aneurysm detected
at initial scan, 72% (n=963) had complete clinical fol-
low-upto10yearsaccordingtotheprotocol;thiscom-
pares with 76% at seven years. Secondly, inability to
follow up deaths because some men may have moved
was 2.7% at 10 years, compared with 2.1% at seven
Table 1 |Deaths related to abdominal aortic aneurysm*, ruptured abdominal aortic aneurysm,
and other causes of death
Category Control group (n=33 887) Invited group (n=33 883)
Deaths related to aneurysm:
<30 days after elective surgery† 13 21
Ruptured aneurysm‡ 251 110
Ruptured aneurysm of unspecified site§ 32 24
Total No 296 155
Hazard ratio (95% CI) 1 (reference) 0.52 (0.43 to 0.63)
Ruptured aneurysm:
Non-fatal rupture 78 42
Total incidence of rupture¶ 374 197
Hazard ratio (95% CI) 1 (reference) 0.52 (0.44 to 0.62)
Other causes of death:
Ischaemic heart disease 2448 2324
Other cardiovascular 1391 1430
Non-cardiovascular** 6346 6365
All deaths 10 481 10 274
Hazard ratio (95% CI) 1 (reference) 0.97 (0.95 to 1.00)
*Codes 441.3-6 (international classification of diseases, ninth revision), or equivalently codes I71.3-4 and 8-9
(international classification of diseases, 10th revision).
†Those with ICD-9 codes 441.3-6 who died within 30 days of elective surgery are classified here.
‡ICD-9 codes 441.3 (ruptured abdominal aortic aneurysm) and 441.4 (abdominal aortic aneurysm without
mention of rupture), and all deaths occurring within 30 days of emergency surgery for abdominal aortic
aneurysm.
§ICD-9 codes 441.5 (ruptured aortic aneurysm at unspecified site) and 441.6 (aortic aneurysm at unspecified
site without mention of rupture).
¶Deaths related to abdominal aortic aneurysm plus incidence of non-fatal ruptured abdominal aortic aneurysm.
**Includes 19 deaths of unknown cause.
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Fig 1 | Cumulative deaths related to abdominal aortic
aneurysm, by time since randomisation
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last known to be alive.
Overall, 155 deaths related to abdominal aortic
aneurysm(absoluterisk0.46%)occurredintheinvited
groupcomparedwith296(0.87%)inthecontrolgroup,
arelativeriskreductionof48%(hazardratio0.52,95%
confidence interval 0.43 to 0.63; table 1). The benefit
seeninearlieryearsoffollow-upwasmaintainedinthe
later years of follow-up, with continued divergence of
the cumulative curves of deaths related to abdominal
aorticaneurysminthetwogroups(fig1).Themeanage
at death was similar in the invited and control groups
(75.0 v 75.4 years). Non-fatal ruptures of abdominal
aorticaneurysms were also abouthalved in the invited
group (table 1). Twenty one men in the invited group
diedwithin30daysofelectivesurgery,andanothersix
men after more than 30 days. Additionally, despite
being invited for screening, 170 men subsequently
had a ruptured aneurysm. Many of these were, how-
ever, excluded from the potential benefit of screening
—for example, among those who did not attend
screening, those who did not keep an outpatient
appointment, those who refused surgery, and those
who were considered unfit for surgery (table 2).
Among those who could potentially benefit from
screening, some aneurysms ruptured between recall
scans, pending a decision about surgery and while
awaiting surgery (table 2). Twenty five ruptures also
occurred after the men had had normal initial scans,
of which 19 were fatal. The rate of these ruptures
increased noticeably after eight years of follow-up
(fig 2). In years 8, 9, and 10 (when censoring impacts
on the follow-up data available) six, six, and three rup-
tures occurred, respectively, with corresponding rup-
ture rates per 10000 person years of 3.0, 3.8, and 5.7.
Time since initial scan, rather than age, was the main
determinant of this increased risk of rupture.
Overthe10years552electiveoperationstookplace
in the invited group and 226 in the control group. The
respective 30 day mortality rates of 4% (21/552) and
6% (13/226) were not significantly different (P=0.23).
Sixty two men underwent emergency surgery in the
invited group compared with 141 in the control
group. The respective 30 day mortality rates of 29%
(18/62)and 36%(50/141)were notsignificantlydiffer-
ent (P=0.37). Nearly all the operations in MASS were
open surgical repairs, with endovascular repair occur-
ring only in the later period of follow-up. Two endo-
vascular repairs were undertaken as emergency
procedures (both patients died within 30 days) and 68
as elective procedures, representing 9% (68/778) of all
elective operations. The 30 day mortality rate for elec-
tive endovascular repair was 3% (2/68).
The benefit of a screening programme is diluted by
those who, despite being invited, do not attend: the
unbiased estimate of the reduction in deaths related
to abdominal aortic aneurysm among men who were
screened was 60% (hazard ratio 0.40, 95% confidence
interval 0.32 to 0.50). This estimate is relevant when
providing information to individuals about the benefit
of screening or when considering the benefit from a
screening programme that achieves an attendance
rate different to the 80% achieved in MASS.
Total mortality at 10 years was about 30% in each
group (table 1). Because deaths related to abdominal
aortic aneurysm comprise about 2% of all deaths and
there were no clear differences in any other causes of
death, only a small difference was found in all cause
mortality (hazard ratio 0.97, 0.95 to 1.00). Although
124fewerdeathsfromischaemicheartdiseaseoccurred
in the invited group, this difference was not statistically
convincing (P=0.06),and the mean age ofthe men who
died was 74.7 in both groups. These findings do not
Table 2 |Timing of incidence of ruptured abdominal aortic aneurysm and deaths in 33 883
men aged 65 or more invited to screening
Category
Incidence of ruptured
abdominal aortic aneurysm
(n=197)*
Deaths
(n=155)
Aneurysm not identified by screening programme
Between randomisation and scan 3 3
After non-attendance at screening (n=6679)† 72 61
After unclear initial scan (n=329) 2 1
After normal initial scan (n=25 541) 25 19
Aneurysm identified by screening programme
Aneurysm <5.5 cm detected (n=727)‡:
Between recall scans 15 9
After non-attendance at outpatient department 15 14
Aneurysm ≥5.5 cm detected (n=607)‡:
After non-attendance at outpatient department 1 1
After refusal of surgery 4 4
After declared unfit for surgery 12 12
Pending decision on surgery 15 6
While awaiting surgery 9 2
After return to surveillance§ 32
After elective surgery:
≤30 days 16 16
>30 days 5 5
*Deaths related to abdominal aortic aneurysm (including all deaths within 30 days of surgery for abdominal
aortic aneurysm) and incidence of non-fatal ruptured abdominal aortic aneurysm
†Includes six deaths after elective surgery (five within 30 days) after incidental detection of abdominal aortic
aneurysm.
‡Aneurysm size based on maximum observed from all scans.
§Aneurysm ≥5.5 cm not confirmed at outpatient visit.
Years since randomisation
R
u
p
t
u
r
e
 
r
a
t
e
 
p
e
r
 
1
0
 
0
0
0
 
p
e
r
s
o
n
 
y
e
a
r
s
0-1.9 2-3.9 4-5.9 6-7.9 8-9.9
0
2
3
4
1
(1)
(4) (4)
(1)
(12)
Fig 2 | Rate of ruptured abdominal aortic aneurysms (number
of ruptures in brackets) in men originally screened as normal,
by time since randomisation. Three more ruptures were
recorded in the limited follow-up after 10 years
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between the groups as a result of screening.
The costs per person were greater in the invited
group (through the costs of screening and more elec-
tivesurgerybutoffsetbyfeweremergencyoperations),
byanaverageof£100(table3).Theextentofreduction
innumberofdeathsrelatedtoabdominalaorticaneur-
ysmintheinvitedgroupledtoanestimatedincremen-
tal cost effectiveness ratio of £7600 (95% confidence
interval£5100to£13000)perlifeyeargainedoverthe
10 years of the trial.
DISCUSSION
Thebenefitofinvitingmenaged65-74toscreeningfor
abdominal aortic aneurysm continues at about the
same rate 7-10 years after screening, as observed in
previous years. The reduction in number of deaths
related to abdominal aortic aneurysm in MASS is esti-
mated as 42% at four years,
4 47% at seven years,
5 and
now 48% at 10 years. This is surprising as it might be
expectedthatrupturesoftheaneurysminthoseorigin-
ally screened as normal and incidental detection of
abdominal aortic aneurysm in the control group
would erode the benefit over time. Being based on a
populationbasedsampleofUKmen,thesefigurescor-
respond to the expected benefit that will derive from
the UK national screening programme. About 1900
deaths each year, half of the deaths related to abdom-
inalaorticaneurysmthatoccurinmenaged65ormore
in the UK,
21 should be prevented in due course by the
screening programme. Such a programme will never
prevent all ruptures but to optimise performance our
resultsshowthatemphasisshouldbeplacedonachiev-
ingahighinitialattendancerateandgoodadherenceto
clinical follow-up, preventing delays in undertaking
surgery, and maintaining a low operative mortality
after elective surgery. More evidence may be needed
to choose the best intervals between recall scans, for
differentsizesofaneurysmlessthan5.5cm
22;anystrat-
egy needs to balance the effectiveness in preventing
ruptures while under surveillance against the costs.
A crucial problem is the extent to which those
screened as normal will go on to develop an aneurysm
that ruptures and whether rescreening of participants
after a normal scan is justified at any stage. We
observed a noticeable increase in ruptures after eight
years of follow-up; although most were fatal, the
absolute numbers remained small. For example, 15
fatal ruptures occurred during years 8-10; over the
sameperiodtherewasanoverallreductionof40deaths
related to abdominal aortic aneurysm in the group
invited to screening compared with the control group.
Hence the deaths due to rupture after a normal scan
seem not to have impacted yet on the diverging curves
from deaths related to abdominal aortic aneurysm
shown in figure 1. Recommending rescreening those
withaninitialnormalscanwouldonlybecomejustified
insubsequentyearsiffutureanalysesshowthatthereis
a further noticeable increase in ruptures in this group
thatisnotsufficientlyoffsetbythereductioninnumber
of deaths related to abdominal aortic aneurysm for
those with an aneurysm detected (or rendered unim-
portant by the overall toll of mortality from all causes).
Cost effectiveness of screening
The survival advantage in terms of life years gained
continues to increase with time, as indicated by the
diverging curves in figure 1. Because the main costs
of the programme (initial screening and elective sur-
gery for those with aneurysm diameter >5.5 cm)
occur early on, whereas the benefit in terms of life
years increases over time, the cost effectiveness
improves when considered over longer time scales.
Using the same unit costs and discount rates as in the
current analysis, the cost per life year gained is esti-
mated as £41000 after four years, £14000 after seven
years, and now £7600 after 10 years. The estimate and
confidence interval at 10 years iswell below the guide-
line figure of around £25000 per life year gained for
the acceptance of medical technologies and inter-
ventions in the NHS.
23 Sensitivity analyses using alter-
native unit costs
5 did not change this conclusion.
Moreover, the estimates from MASS over time are in
line with the figures predicted from a long term health
economic model, which was developed based on the
first four years of follow-up in MASS.
10 This congru-
ence lends credibility to the estimate derived from the
model of £2300 per life year gained over the full life-
time for men aged 65, indicating an extremely cost
effective programme and even more favourable than
estimates from other recent models.
1124
New treatments for aneurysms
New treatments for abdominal aortic aneurysm may
impactonanationalscreeningprogrammeandincrease
its effectiveness. Endovascular repair of aneurysms
rather than conventional open repair is now used more
widely for elective surgery but was used for only 9% of
the elective procedures in MASS. In patients who are fit
for open repair, and anatomically suitable for endo-
vascularrepair,endovascularrepairhasloweroperative
mortality than open repair and fewer deaths related to
abdominal aortic aneurysm in the longer term
25-28;i t
may therefore be preferred by both patients and
surgeons. Reliable evidence comparing endovascular
repair of abdominal aortic aneurysms with open repair
is currently available only up to four years of follow-up;
it shows no difference in all cause mortality
28 but a
Table 3 |Discounted mean costs and effects per person,
based on 10 year follow-up in Multicentre Aneurysm
Screening Study (MASS)
Variable Costs (£)
Survival (life
days)
Control group 108 2743.0
Invited group 208 2747.8
Difference (95% CI) 100 (82 to 118) 4.8 (2.9 to 6.7)
Costperlifeyeargained(95%CI) £7600 (£5100 to £13 000)
£1.00 (€1.18; $1.65).
Costs based on 2008-9 prices; discounting both costs and survival at
3.5% per year. Survival based on deaths related to abdominal aortic
aneurysm, adjusted for other causes of deaths.
RESEARCH
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leaks around the graft or movement of the graft) and
need for reinterventions after endovascular repair.
2627
These incur costs, as does the requirement for surveil-
lance of the graft. Based on the large UK trial of endo-
vascular repair, a cost effectiveness modelling study
concludedthatendovascularrepairwasmoreexpensive
than openrepair, was unlikelyto be cost effective at cur-
rent prices, and should be retained as a research
technology.
29In patients who are not fit for open repair,
the randomised evidence also does not support the use
of endovascular repair.
30 Recent guidance from the
National Institute for Health and Clinical Excellence
31
is more optimistic, however, being based on more
favourable assumptions about the initial costs and later
complications after endovascular repair. It concluded
that endovascular repair was an appropriate treatment
for abdominal aortic aneurysm, both for fit and unfit
patients,provideddueaccountwastakenofthepatient’s
age and fitness, and the size and morphology of the
aneurysm. It is clear from these reports that what is
required is robust evidence, principally in terms of
longer term follow-up from randomised trials of endo-
vascular repair. Until this is available it may be reason-
able to assume that endovascular repair has similar cost
effectiveness to open repair, a conclusion supported by
somerecentevidence suggestingroughlyequal costsfor
open repair and endovascular repair over 2.5 years.
32
On this basis, the overall cost effectiveness of screening
forabdominalaorticaneurysmwouldnotbeexpectedto
change much if endovascular repair was used, when
appropriate, in place of elective open repair. General
agreementisthatendovascularrepairshouldnotbecur-
rently used for emergency repairs, except in the context
of research studies.
31
Although patients with abdominal aortic aneurysm
should receive a statin because of their high general
cardiovascular risk,
33 and the possibility that statins
reduce the expansion rate of aneurysms,
34 to date no
medical treatments have been convincingly shown to
reduce the rate of aneurysm expansion over time.
Results from observational data suggesting that angio-
tensin converting enzyme inhibitors may be an effec-
tive treatment
35 require confirmation in a large scale
randomised trial.
Limitations of the study
Some potential limitations of the current analyses of
MASS should be mentioned. The inclusion of deaths
from aortic aneurysm at an unspecified site may have
provided a conservative estimate of the benefit of
screening,sincetheuseofcodes441.5and441.6(inter-
national classification of diseases, ninth revision) may
resultintheinclusionofsomedeathsrelatedtothoracic
aorticaneurysm. Investigationofthe accuracy ofcause
ofdeathcodingonthedeathcertificatesinthefirstfour
years of follow-up was carried out by an independent
mortality working party blinded to group allocation,
and showed that inaccuracies in coding had a minimal
impactonstudyoutcomes.
4Thequalityoflifedatacol-
lected in the trial around the time of screening showed
noclearadverseorbeneficialeffectsofscreeningorany
long term effects after surgery.
436Using general popu-
lationagespecificnormsforqualityoflife,
37thecostper
quality adjusted life year (QALY) in MASS at 10 years
was£9400(95%confidenceinterval£6300to£16000).
Although the loss to follow-up for deaths was small
as participants were tracked through their NHS num-
ber, identification of all patients who had undergone
surgical repair was more difficult to achieve. Surgical
follow-up was through review of data on surgery for
abdominalaorticaneurysmcarriedoutatthelocalhos-
pitals in each screening area, thus missing operations
among those patients who had moved away or had
surgery at other hospitals; subsequent deaths within
30 days of surgery would not necessarily be recorded
as related to abdominal aortic aneurysm on the death
certificate. We were able to estimate the extent of this
problem in one MASS centre, by calculating the num-
ber of deaths in hospital that occurred outside the area
from information on death certificates; this gave a
value of 278/4241 (7%). Since this proportion is
small, indicating that few people of this age group
move out of the area and would be potentially lost to
surgical follow-up, it should only have a minor impact
on the trial’s results.
Conclusions
We conclude that the UK national screening pro-
gramme for abdominal aortic aneurysm should, in
the long term, halve the mortality rate related to
abdominal aortic aneurysm in men aged 65 or more,
and that it will be a cost effective programme for the
NHS. Rescreening of those originally screened as nor-
mal is not currently justified.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Ultrasound screening for abdominal aortic aneurysm in men aged 65 or more reduces
mortality in the short term
Rupture of aneurysm in those originally screened as normal, and incidental detection of
aneurysms, could reduce the effectiveness of screening over time
WHAT THIS STUDY ADDS
The mortality benefit of one-off screening of men aged 65-74 for abdominal aortic aneurysm
is maintained up to 10 years, despite an increase in ruptures among those screened as
normal
About half of all aneurysm related deaths should be prevented by a national screening
programme
The long term cost effectiveness of screening is highly favourable
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